HK1083587A1 - Body weight gain inhibitor - Google Patents

Body weight gain inhibitor

Info

Publication number
HK1083587A1
HK1083587A1 HK06103674.1A HK06103674A HK1083587A1 HK 1083587 A1 HK1083587 A1 HK 1083587A1 HK 06103674 A HK06103674 A HK 06103674A HK 1083587 A1 HK1083587 A1 HK 1083587A1
Authority
HK
Hong Kong
Prior art keywords
body weight
weight gain
provides
pharmaceutical agent
gain inhibitor
Prior art date
Application number
HK06103674.1A
Other languages
English (en)
Inventor
Zen-Ichi Terashita
Keiji Kusumoto
Fuminari Yamaguchi
Yoshimi Imura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1083587A1 publication Critical patent/HK1083587A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06103674.1A 2002-12-27 2006-03-23 Body weight gain inhibitor HK1083587A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002380386 2002-12-27
PCT/JP2003/016656 WO2004060399A1 (ja) 2002-12-27 2003-12-25 体重増加抑制剤

Publications (1)

Publication Number Publication Date
HK1083587A1 true HK1083587A1 (en) 2006-07-07

Family

ID=32708435

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103674.1A HK1083587A1 (en) 2002-12-27 2006-03-23 Body weight gain inhibitor

Country Status (9)

Country Link
US (1) US7582662B2 (xx)
EP (1) EP1579872B8 (xx)
KR (1) KR101092279B1 (xx)
CN (1) CN100438911C (xx)
AT (1) ATE551056T1 (xx)
AU (1) AU2003292775A1 (xx)
CA (1) CA2511737A1 (xx)
HK (1) HK1083587A1 (xx)
WO (1) WO2004060399A1 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
MX2007003716A (es) * 2004-10-07 2007-04-23 Takeda Pharmaceutical Agente para la profilaxis o tratamiento del sindrome metabolico.
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
BRPI0809522A2 (pt) * 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192951A3 (en) * 1996-04-05 2004-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
US6177587B1 (en) 1997-05-26 2001-01-23 Takeda Chemical Industries, Ltd. Production method of aminobenzene compound
JP3003030B2 (ja) 1997-05-26 2000-01-24 武田薬品工業株式会社 アミノベンゼン化合物の製造法
DE69914460T2 (de) * 1998-03-04 2004-10-28 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
RU2213738C2 (ru) * 1998-05-11 2003-10-10 Такеда Кемикал Индастриз, Лтд. Производные оксииминоалкановой кислоты, фармацевтическая композиция и средство для регуляции ретиноидных рецепторов
EP1197226B1 (en) 1999-07-21 2007-11-21 Takeda Pharmaceutical Company Limited Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
HUP0203837A2 (hu) 1999-11-10 2003-03-28 Takeda Chemical Industries, Ltd. Testtömegnövekedést gátló szerek
CA2400124C (en) 2000-02-18 2010-12-14 Kazuaki Ikeya Tnf-.alpha. inhibitors
CA2400845A1 (en) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
KR20020089437A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기 화합물의 배합
SK14642002A3 (sk) 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor
US20030083342A1 (en) 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
WO2002074340A1 (fr) 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
EP1452176A4 (en) 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE

Also Published As

Publication number Publication date
WO2004060399A1 (ja) 2004-07-22
AU2003292775A1 (en) 2004-07-29
KR101092279B1 (ko) 2011-12-13
KR20050085905A (ko) 2005-08-29
CN1756567A (zh) 2006-04-05
EP1579872B1 (en) 2012-03-28
CN100438911C (zh) 2008-12-03
EP1579872B8 (en) 2012-11-07
EP1579872A1 (en) 2005-09-28
US7582662B2 (en) 2009-09-01
CA2511737A1 (en) 2004-07-22
ATE551056T1 (de) 2012-04-15
EP1579872A4 (en) 2006-03-22
US20060069133A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE60231407D1 (de) Hemmende antikörper der her3-aktivität
TW200635588A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2003072040A3 (en) Administration of agents for the treatment of inflammation
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
IN2005KO00312A (xx)
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
WO2005044192A3 (en) Triazole compounds and uses related thereto
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
WO2005056524A3 (en) Therapeutic agents useful for treating pain
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
EP1938814A4 (en) PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1082668A1 (en) Remedies for glomerular diseases
TR200002969T2 (tr) Farmasötik bileşim.
HUP0202745A2 (hu) Profilaktikus és terápiás szerek szembetegségek kezelésére
HK1083587A1 (en) Body weight gain inhibitor
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
WO2002055022A3 (en) Active metabolite of antifungal compound
TW200514553A (en) Therapeutic agent for hepatitis C
WO2005035500A3 (en) Therapeutic agents useful for treating pain
TW200626590A (en) Triazole derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151225